Partners, Samsung to collaborate on digital, mobile health

Partners HealthCare has entered into a new partnership with Samsung Electronics to develop the next generation of personalized digital and mobile solutions for health and wellness.

The first phase of this collaboration will include software development and clinical research to deliver tools to improve chronic disease management, according to a release.  

“This project represents the start of how smart technology, intelligent algorithms and world class clinical expertise can be combined to change the paradigm of care delivery,” said Kamal Jethwani, MD, MPH, senior director, Connected Health Innovation at Partners, who will lead this research initiative which will launch in a clinical trial in June.

"This unprecedented new partnership brings to bear the unique strengths of Samsung Electronics, the Partners Connected Health team and our leading healthcare providers, to expand the boundaries of digital health technology," said Joseph C. Kvedar, MD, Partner' vice president, Connected Health. "Combining our real-world clinical experience and implementation of connected health solutions with their leading mobile and IT technology, we believe that, together, we can re-imagine the future of health and wellness and deliver innovative, convenient and powerful personal connected health tools."

Samsung's Digital Media and Communications R&D Center will oversee this program for the company.

 

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.